Clinical Trials Logo

Clinical Trial Summary

For permanent coronary stents, reduction of thickness of struts have become one of the most important innovation, being related to easier manipulation, reduced risk of stent thrombosis and low rate of revascularization. Consequently the investigators performed a multicenter registry enrolling all consecutive patients treated with very thin stents for ULM or bifurcation.


Clinical Trial Description

For permanent coronary stents, reduction of thickness of struts have become one of the most important innovation, being related to easier manipulation, reduced risk of stent thrombosis and low rate of revascularization. Previous studies do not have enough power to detect potential significant difference for ULM or bifurcation lesions. Consequently the investigators performed a multicenter registry enrolling all consecutive patients treated with Biomatrix Flex, Xience Alpine, Ultimaster, Resolute Onyx and Synergy. MACE (a composite end point of death, myocardial infarction, target lesion revascularization and stent thrombosis) will be the primary end point, while its single components will be the secondary ones. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03544294
Study type Observational [Patient Registry]
Source Azienda Ospedaliera Città della Salute e della Scienza di Torino
Contact
Status Completed
Phase
Start date June 1, 2017
Completion date May 30, 2018

See also
  Status Clinical Trial Phase
Active, not recruiting NCT01205776 - EXCEL Clinical Trial N/A
Completed NCT01182428 - XIENCE V: SPIRIT WOMEN Sub-study Phase 4
Completed NCT01231035 - REsponsiveness to CLOpidogrel and Stent-related Events in Acute Coronary Syndromes (RECLOSE 2 - ACS) N/A
Completed NCT01205789 - EXCEL Clinical Trial (Universal Registry) N/A
Completed NCT00647504 - Prospective Clinical Observational Registry Including Consecutive Patients With In-stent Restenosis or Stent Thrombosis N/A
Active, not recruiting NCT00905008 - Long-Term Safety of Drug Eluting Stents in the "Real World" (FReIburger STent Registry) N/A
Recruiting NCT03118895 - Leaders Free III: BioFreedomâ„¢ Clinical Trial N/A
Unknown status NCT01249027 - XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval, Single-Arm Study N/A
Recruiting NCT03209843 - Post-stenting Assessment of Reendothelialization With OFDI After CTO Procedure (PERFECTO) N/A
Completed NCT01086228 - XIENCE V/PROMUS Everolimus-Eluting Stent System Post-marketing Surveillance Protocol for Japan N/A
Completed NCT00998127 - Patterns of Non-Adherence to Dual Anti-Platelet Regimen In Stented Patients N/A
Completed NCT00180479 - SPIRIT III Clinical Trial of the XIENCE V® Everolimus Eluting Coronary Stent System (EECSS) Phase 3
Active, not recruiting NCT01894152 - XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS) China Single-Arm Study N/A
Completed NCT00496938 - XIENCE V: SPIRIT WOMEN Phase 4
Recruiting NCT02617290 - Assessment of Loading With the P2Y12 Inhibitor Ticagrelor or Clopidogrel to Halt Ischemic Events in Patients Undergoing Elective Coronary Stenting Phase 3
Completed NCT01410539 - Mechanism Of Stent Thrombosis (MOST) Study Phase 4
Completed NCT00822536 - Optimal Duration of Dual Antiplatelet Therapy After Drug-eluting Stent Implantation Phase 4
Completed NCT00914368 - Tailoring Of Platelet Inhibition to Avoid Stent Thrombosis Phase 2
Terminated NCT00606151 - PeriOperative Bridging - Perioperative Anticoagulation in the Setting of Recent Intracoronary Drug Eluting Stents N/A
Completed NCT00753753 - VerifyNow French Registry N/A